Return on investment (ROI), also called return on invested capital, is the profit a company earns for every dollar of long-term capital from both lenders and shareholders, shown as a percentage. It is net income divided by long-term debt plus shareholder equity, and the table shows both amounts. Because debt is included in the base, ROI does not rise just because a company replaces equity with borrowing, which sets it apart from ROE. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Cue Biopharma, Inc. roi for the quarter ending 2024-09-30 was -145.34%, a change of -45.22% year-over-year.
Cue Biopharma, Inc. roi for the quarter ending 2024-06-30 was -168.26%, a change of -75.88% year-over-year.
Cue Biopharma, Inc. roi for the quarter ending 2024-03-31 was -134.04%, a change of -54.36% year-over-year.
Cue Biopharma, Inc. roi for the quarter ending 2023-12-31 was -112.03%, a change of -42.01% year-over-year.
Cue Biopharma, Inc. roi for fiscal 2024 was -231.95%, a change of -109.18% from fiscal 2023.
Cue Biopharma, Inc. roi for fiscal 2023 was -122.77%, a change of -50.93% from fiscal 2022.
Cue Biopharma, Inc. roi for fiscal 2022 was -71.84%.